Résultats de la recherche - Sachdev Thomas

  • Résultat(s) 1 - 13 résultats de 13
Affiner les résultats
  1. 1
    Goblet cell carcinoid of the appendix – diagnostic challenges and treatment updates: a case report and review of the literature

    Goblet cell carcinoid of the appendix – diagnostic challenges and treatment updates: a case report and review of the literature par Gilmore, Gregory, Jensen, Kristin, Saligram, Shreyas, Sachdev, Thomas P., Arekapudi, Subramanyeswara R.

    Publié 2018
    Accéder au texte intégral Accéder au texte intégral Accéder au texte intégral
    Texte
    Ajouter aux favoris
    Enregistré dans:
  2. 2
    Randomized Phase II Trial of Erlotinib or Standard Chemotherapy in Patients With Advanced Non–Small-Cell Lung Cancer and a Performance Status of 2

    Randomized Phase II Trial of Erlotinib or Standard Chemotherapy in Patients With Advanced Non–Small-Cell Lung Cancer and a Performance Status of 2 par Rogério Lilenbaum, Rita Axelrod, Sachdev Thomas, Afshin Dowlati, L. Seigel, Donald G. Albert, Karsten Witt, D. Botkin

    Publié 2008
    Accéder au texte intégral Accéder au texte intégral
    Artigo
    Ajouter aux favoris
    Enregistré dans:
  3. 3
    A phase II trial of Triapine® (NSC# 663249) and gemcitabine as second line treatment of advanced non-small cell lung cancer: Eastern Cooperative Oncology Group Study 1503

    A phase II trial of Triapine® (NSC# 663249) and gemcitabine as second line treatment of advanced non-small cell lung cancer: Eastern Cooperative Oncology Group Study 1503 par Anne M. Traynor, Ju-Whei Lee, Gerald K. Bayer, John M. Tate, Sachdev Thomas, Miroslaw Mazurczak, David L. Graham, Jill Kolesar, Joan H. Schiller

    Publié 2009
    Accéder au texte intégral
    Artigo
    Ajouter aux favoris
    Enregistré dans:
  4. 4
    Placebo-Controlled Trial to Determine the Effectiveness of a Urea/Lactic Acid–Based Topical Keratolytic Agent for Prevention of Capecitabine-Induced Hand-Foot Syndrome: North Central Cancer Treatment Group Study N05C5

    Placebo-Controlled Trial to Determine the Effectiveness of a Urea/Lactic Acid–Based Topical Keratolytic Agent for Prevention of Capecitabine-Induced Hand-Foot Syndrome: North Centr... par Sherry L. Wolf, Rui Qin, Smitha Menon, Kendrith M. Rowland, Sachdev Thomas, Robert Delaune, Diana L. Christian, Eduardo R. Pajon, Daniel Satele, Jeffrey L. Berenberg, Charles L. Loprinzi

    Publié 2010
    Accéder au texte intégral Accéder au texte intégral
    Artigo
    Ajouter aux favoris
    Enregistré dans:
  5. 5
    Phase III Randomized, Placebo-Controlled, Double-Blind Trial of Risedronate for the Prevention of Bone Loss in Premenopausal Women Undergoing Chemotherapy for Primary Breast Cancer

    Phase III Randomized, Placebo-Controlled, Double-Blind Trial of Risedronate for the Prevention of Bone Loss in Premenopausal Women Undergoing Chemotherapy for Primary Breast Cancer par Stephanie L. Hines, Betty A. Mincey, Jeff A. Sloan, Sachdev Thomas, Elaine G. Chottiner, Charles L. Loprinzi, Mark D. Carlson, Philip J. Atherton, Muhammad Salim, Edith A. Perez

    Publié 2008
    Accéder au texte intégral Accéder au texte intégral
    Artigo
    Ajouter aux favoris
    Enregistré dans:
  6. 6
    Carboplatin and Paclitaxel in Combination With Either Vorinostat or Placebo for First-Line Therapy of Advanced Non–Small-Cell Lung Cancer

    Carboplatin and Paclitaxel in Combination With Either Vorinostat or Placebo for First-Line Therapy of Advanced Non–Small-Cell Lung Cancer par Suresh S. Ramalingam, Michael L. Maitland, Paul Frankel, Athanassios Argiris, Marianna Koczywas, Barbara J. Gitlitz, Sachdev Thomas, Igor Espinoza‐Delgado, Everett E. Vokes, David R. Gandara, Chandra P. Belani

    Publié 2009
    Accéder au texte intégral
    Artigo
    Ajouter aux favoris
    Enregistré dans:
  7. 7
    <i>TP53</i> Gain-of-Function and Non–Gain-of-Function Mutations Are Associated With Differential Prognosis in Advanced Pancreatic Ductal Adenocarcinoma

    <i>TP53</i> Gain-of-Function and Non–Gain-of-Function Mutations Are Associated With Differential Prognosis in Advanced Pancreatic Ductal Adenocarcinoma par Minggui Pan, Chen Jiang, Zheyang Zhang, Ninah Achacoso, Stacey E. Alexeeff, Aleyda V. Solorzano, Pam Tse, Elaine Chung, Tilak Sundaresan, Jennifer M. Suga, Sachdev Thomas, Laurel A. Habel

    Publié 2023
    Accéder au texte intégral
    Artigo
    Ajouter aux favoris
    Enregistré dans:
  8. 8
    Cediranib in patients with malignant mesothelioma: A phase II trial of the University of Chicago Phase II Consortium

    Cediranib in patients with malignant mesothelioma: A phase II trial of the University of Chicago Phase II Consortium par Nicholas Campbell, Rangesh Kunnavakkam, Natasha B. Leighl, Mark Vincent, David R. Gandara, Marianna Koczywas, Barbara J. Gitlitz, Edem Agamah, Sachdev Thomas, Walter M. Stadler, Everett E. Vokes, Hedy L. Kindler

    Publié 2012
    Accéder au texte intégral
    Artigo
    Ajouter aux favoris
    Enregistré dans:
  9. 9
    Chemotherapy With or Without Maintenance Sunitinib for Untreated Extensive-Stage Small-Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase II Study—CALGB 30504 (Alliance)

    Chemotherapy With or Without Maintenance Sunitinib for Untreated Extensive-Stage Small-Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase II Study—CALGB 30504 (... par Neal Ready, Herbert Pang, Lin Gu, Gregory A. Otterson, Sachdev Thomas, Antonius A. Miller, Maria Q. Baggstrom, Gregory A. Masters, Stephen L. Graziano, Jeffrey Crawford, Jeffrey A. Bogart, Everett E. Vokes

    Publié 2015
    Accéder au texte intégral Accéder au texte intégral
    Artigo
    Ajouter aux favoris
    Enregistré dans:
  10. 10
    <i>TP53</i> Gain-of-Function and Non–Gain-of-Function Mutations Are Differentially Associated With Sidedness-Dependent Prognosis in Metastatic Colorectal Cancer

    <i>TP53</i> Gain-of-Function and Non–Gain-of-Function Mutations Are Differentially Associated With Sidedness-Dependent Prognosis in Metastatic Colorectal Cancer par Minggui Pan, Chen Jiang, Pam Tse, Ninah Achacoso, Stacey E. Alexeeff, Aleyda V. Solorzano, Elaine Chung, Wenwei Hu, Thach‐Giao Truong, Amit Arora, Tilak Sundaresan, Jennifer M. Suga, Sachdev Thomas, Laurel A. Habel

    Publié 2021
    Accéder au texte intégral
    Artigo
    Ajouter aux favoris
    Enregistré dans:
  11. 11
    Phase III Randomized, Placebo-Controlled, Double-Blind Trial of Celecoxib in Addition to Standard Chemotherapy for Advanced Non–Small-Cell Lung Cancer With Cyclooxygenase-2 Overexpression: CALGB 30801 (Alliance)

    Phase III Randomized, Placebo-Controlled, Double-Blind Trial of Celecoxib in Addition to Standard Chemotherapy for Advanced Non–Small-Cell Lung Cancer With Cyclooxygenase-2 Overexp... par Martin J. Edelman, Xiaofei Wang, Lydia Hodgson, Richard T. Cheney, Maria Q. Baggstrom, Sachdev Thomas, Ajeet Gajra, Erin M. Bertino, Karen L. Reckamp, Julian R. Molina, Joan H. Schiller, Kisha Mitchell-Richards, Paula N. Friedman, Jon Ritter, Ginger L. Milne, Olwen Hahn, Thomas E. Stinchcombe, Everett E. Vokes

    Publié 2017
    Accéder au texte intégral
    Artigo
    Ajouter aux favoris
    Enregistré dans:
  12. 12
    Phase II Study of the Oral MEK Inhibitor Selumetinib in Advanced Acute Myelogenous Leukemia: A University of Chicago Phase II Consortium Trial

    Phase II Study of the Oral MEK Inhibitor Selumetinib in Advanced Acute Myelogenous Leukemia: A University of Chicago Phase II Consortium Trial par Nitin Jain, Emily Curran, Neil M. Iyengar, Ernesto Díaz-Flores, Rangesh Kunnavakkam, Leslie Popplewell, Mark Kirschbaum, Theodore Karrison, Harry P. Erba, Margaret Green, Xavier Poiré, Greg Koval, Kevin Shannon, Poluru L. Reddy, Loren Joseph, Ehab Atallah, Philip A. Dy, Sachdev Thomas, Scott E. Smith, L. Austin Doyle, Walter M. Stadler, Richard A. Larson, Wendy Stock, Olatoyosi Odenike

    Publié 2013
    Accéder au texte intégral
    Artigo
    Ajouter aux favoris
    Enregistré dans:
  13. 13
    Development and validation of an integrative pan-solid tumor predictor of PD-1/PD-L1 blockade benefit

    Development and validation of an integrative pan-solid tumor predictor of PD-1/PD-L1 blockade benefit par Scott A. Tomlins, Nickolay A. Khazanov, Benjamin J. Bulen, Daniel H. Hovelson, Melissa J. Shreve, Laura E. Lamb, Marc Matrana, Mark E. Burkard, Eddy S. Yang, William J. Edenfield, Elizabeth Claire Dees, Adedayo A. Onitilo, Michael A. Thompson, Gary L. Buchschacher, Alan M. Miller, Alexander Menter, Benjamin M. Parsons, Timothy R. Wassenaar, Leon C. Hwang, Jennifer M. Suga, Robert D. Siegel, William Irvin, Suresh Nair, Jennifer N. Slim, Jamal Misleh, Jamil Khatri, Gregory A. Masters, Sachdev Thomas, Malek M. Safa, Daniel M. Anderson, Kat Kwiatkowski, Khalis Mitchell, T. Hu-Seliger, Stephanie Drewery, Andrew Fischer, Komal Plouffe, Eric Czuprenski, Jennifer Hipp, Travis Reeder, Hana Vakil, D. Bryan Johnson, Daniel R. Rhodes

    Publié 2023
    Accéder au texte intégral Accéder au texte intégral
    Artigo
    Ajouter aux favoris
    Enregistré dans:

Outils de recherche: